Press release
Global NASH Market Key Players, Demands, Trends, Share, Size, Covid-19 Impact, Sales, Growth and Forecasts to 2026
The Global NASH market valued at USD 3369.12 Million in the year 2020 is projected to grow due to growth in demand for ideal NASH therapeutics, surge in the prevalence of NASH, and expected launch of pipeline drugs during the forecast period. The market is expected to be driven by rise in advanced technology such as advanced clinical trials, special MRI technology, called MR-EFF (elastography fat fraction) to determine the percentage of fat and scarring present. This non-invasive diagnostic tool may eliminate the need for a liver biopsy.Get Free Sample Copy of this Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=4298845
Lifestyle interventions are the first-line approach to manage patients with NASH. If NASH is suspected, the patient will undergo a liver biopsy. During this procedure, a needle is used to remove a small piece of tissue from the liver, which will then be examined under a microscope. This allows the physician to determine if any scarring or inflammation of the liver tissue has occurred. Patients are usually sedated during the liver biopsy.
North America holds the major market share in 2020 with Canada’s influence in global NASH markets cannot go unnoticed which is propelling the regional industry outlook.
On the basis of Sales Channel, Retail Pharmacy is expected to hold significant share in the market over the forecast period due to certain biopharmaceutical manufacturers or companies that sell their drugs to few retail pharmacies so they will always have an advantage with these medications.
Although, the Covid-19 pandemic have taken a major toll on the market dynamics, despite which market seems to grow moderately with time but major concerns may be seen in the future such as the R&D efforts and ability to raise funds. The pandemic could also affect the operations of the FDA, EMA and other health authorities, which could delay clinical development efforts and the review and approval of product candidates, including OCA for liver fibrosis due to NASH.
Get 20% Discount on this Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=4298845
Scope of the Report
- The report analyses the NASH Market by value (USD Million).
- The report analyses the NASH Market by Sales Channel Hospital Pharmacy, Online Provider, Retail Pharmacy.
- The report analyses the NASH Market by By Drug Type Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Others.
- The Global NASH Market has been analysed By Country - United States, Canada, Germany, France, United Kingdom, Italy, Japan, China, India, Mexico, Brazil
- The key insights of the report have been presented through the frameworks of SWOT analysis. Also, the attractiveness of the market has been presented by region, by Sales Channel, by Drug Type. Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis AG, 3M Company, Zydus Cadila, Intercept Pharmaceuticals, SHIRE PLC , Allergan plc( Tobira), Genfit SA, Astra Zeneca, Horizon Therapeutics, Gilead Sciences.
- The report presents the analysis of NASH market for the historical period of 2016-2020 and the forecast period of 2021-2026.
Key Target Audience
- Healthcare an Pharmaceutical Companies
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=4298845
Table of Contents
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. NASH Market: Product Overview
4. Global NASH Market: An Analysis
4.1 Market Size, By Value, Year 2016-2020
4.2 Market Size, By Value, Year 2021-2026
4.3 Impact of COVID-19 on NASH Market
5. Global NASH Market Segmentation, By Sales Channel (Value)
5.1 Global NASH Market: Segment Analysis
5.2 Competitive Scenario of NASH Market: By Sales Channel (2020 & 2026)
5.3 By Hospital Pharmacy - Market Size and Forecast (2016-2026)
5.4 By Online Provider- Market Size and Forecast (2016-2026)
5.5 By Retail Pharmacy-Market Size and Forecast (2016-2026)
6. Global NASH Market Segmentation, By Drug Type (Value)
6.1 Global NASH Market: Segment Analysis
6.2 Competitive Scenario of Global NASH Market: By Drug Type (2021 & 2026)
6.3 By Vitamin E & Pioglitazone - Market Size and Forecast (2016-2026)
6.4 By Ocaliva - Market Size and Forecast (2016-2026)
6.5 By Elafibranor - Market Size and Forecast (2016-2026)
6.6 By Selonsertib & Cenicriviroc - Market Size and Forecast (2016-2026)
6.7 By Others ñ Market Size and Forecast (2016-2026)
7. Global NASH Market: Regional Analysis
7.1 Competitive Scenario of Global NASHMarket: By Region (2021 & 2026)
8. North America NASH Market: An Analysis
8.1 North America NASH Market by value: Size and Forecast (2016-2026)
8.2 Major players in North America NASH Market
8.3 Market Segmentation By Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy)
8.4 Market Segmentation By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Others)
8.5 North America NASH Market: Country Analysis
8.6 Market Opportunity Chart of North America NASH Market- By Country, By Value (Year-2026)
8.7 Competitive Scenario of North America NASH Market ñ By Country (2020 & 2026)
8.8 United States NASH Market: Size and Forecast (2016-2026)
8.9 United States NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
8.10 Canada NASH Market: Size and Forecast (2016-2026)
8.11 Canada NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
9. Europe NASH Market: An Analysis
9.1 Europe NASH Market by value: Size and Forecast (2016-2026)
9.2 Major players in European NASH Market
9.3 Market Segmentation By Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy)
9.4 Market Segmentation By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Others)
9.5 Europe NASH Market: Country Analysis
9.6 Market Opportunity Chart of Europe NASH Market - By Country, By Value (Year-2026)
9.7 Competitive Scenario of Europe NASH Market ñ By Country (2020 & 2026)
9.8 Germany NASH Market: Size and Forecast (2016-2026)
9.9 Germany NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
9.10 France NASH Market: Size and Forecast (2016-2026)
9.11 France NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
9.12 United Kingdom NASH Market: Size and Forecast (2016-2026)
9.13 United Kingdom NASH Market Segmentation By Sales Channel, By Drug Type(2016-2026)
9.14 Italy NASH Market: Size and Forecast (2016-2026)
9.15 Italy NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
10. Asia Pacific NASH Market: An Analysis
10.1 Asia pacific NASH Market by value: Size and Forecast (2016-2026)
10.2 Major players in Asia Pacific NASH Market
10.3 Market Segmentation By Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy)
10.4 Market Segmentation By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Others)
10.5 Asia Pacific NASH Market: Country Analysis
10.6 Market Opportunity Chart of Asia Pacific NASH Market - By Country, By Value (Year-2026)
10.7 Competitive Scenario of Asia Pacific NASH Market ñ By Country (2020 & 2026)
10.8 Japan NASH Market: Size and Forecast (2016-2026)
10.9 Japan NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
10.10 China NASH Market: Size and Forecast (2016-2026)
10.11 China NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
10.12 India NASH Market: Size and Forecast (2016-2026)
10.13 India NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
11. Latin America & Middle East Africa NASH Market: An Analysis
11.1 LAMEA NASH Market by value: Size and Forecast (2016-2026)
11.2 Market Segmentation By Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy)
11.3 Market Segmentation By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Others)
11.4 LAMEA NASH Market: Country Analysis
11.5 Market Opportunity Chart of LAMEA NASH Market - By Country, By Value (Year-2026)
11.6 Competitive Scenario of LAMEA NASH Market ñ By Country (2020 & 2026)
11.7 Mexico NASH Market: Size and Forecast (2016-2026)
11.8 Mexico NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
11.9 Brazil NASH Market: Size and Forecast (2016-2026)
11.10 Brazil NASH Market Segmentation By Sales Channel, By Drug Type (2016-2026)
12. Global NASH Market Dynamics
12.1 Global NASH Market Drivers
12.2 Global NASH Market Restraints
12.3 Global NASH Market Trends
13. Market Attractiveness and Strategic Analysis
13.1 Market Attractiveness
13.1.1 Market Attractiveness Chart of Global NASH Market - By Sales Channel (Year 2026)
13.1.2 Market Attractiveness Chart of Global NASH Market - By Drug Type (Year 2026)
13.1.3 Market Attractiveness Chart of Global NASH Market ñ By Region (Year 2026)
14. Competitive Landscape
14.1 Market Share of global leading companies
14.2 SWOT Analysis
15.Company Profiles (Business Description, Financial Analysis, Business Strategy)
15.1 Novartis AG
15.2 3 M Company
15.3 Zydus Cadila
15.4 Intercept Pharmaceutical
15.5 Shire PLC
15.6 Allergan plc ( Tobira)
15.7 Genfit SA
15.8 Astra Zeneca
15.9 Horizon Therapeutics
15.10 Gilead Science
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
+ 1 888 391 5441
sales@reportsandreports.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global NASH Market Key Players, Demands, Trends, Share, Size, Covid-19 Impact, Sales, Growth and Forecasts to 2026 here
News-ID: 2266170 • Views: …
More Releases from ReportsnReports
DeviceCon Series 2024 - UK Edition | MarketsandMarkets
Future Forward: Redefining Healthcare with Cutting-Edge Devices
Welcome to DeviceCon Series 2024 - Where Innovation Meets Impact!
Join us on March 21-22 at Millennium Gloucester Hotel, 4-18 Harrington Gardens, London SW7 4LH for a groundbreaking convergence of knowledge, ideas, and technology. MarketsandMarkets proudly presents the DeviceCon Series, an extraordinary blend of four conferences that promise to redefine the landscape of innovation in medical and diagnostic devices.
Register Now @ https://events.marketsandmarkets.com/devicecon-series-uk-edition-2024/register
MarketsandMarkets presents…
5th Annual MarketsandMarkets Infectious Disease and Molecular Diagnostics Confer …
London, March 7, 2024 - MarketsandMarkets is thrilled to announce the eagerly awaited 5th Annual Infectious Disease and Molecular Diagnostics Conference, scheduled to take place on March 21st - 22nd, 2024, at the prestigious Millennium Gloucester Hotel, located at 4-18 Harrington Gardens, London SW7 4LH.
This conference promises to be a groundbreaking event, showcasing the latest trends and insights in diagnosis, as well as unveiling cutting-edge technologies that are revolutionizing the…
Infection Control, Sterilization & Decontamination Conference |21st - 22nd March …
MarketsandMarkets is pleased to announce its 8th Annual Infection Control, Sterilisation, and Decontamination in Healthcare Conference, which will take place March 21-22, 2024, in London, UK. With the increased risk of infection due to improper sterilisation and decontamination practices, the safety of patients and healthcare workers is of paramount importance nowadays.
Enquire Now @ https://events.marketsandmarkets.com/infection-control-sterilization-and-decontamination-conference/
This conference aims to bring together all the stakeholders to discuss the obstacles in achieving…
Breast Augmentation Market Key Players, Demands, Cost, Size, Procedure, Shape, S …
The global Breast Augmentation Market in terms of revenue was estimated to be worth $900 million in 2020 and is poised to reach $1,692 million by 2025, growing at a CAGR of 13.4% from 2020 to 2025. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying…
More Releases for NASH
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
IQ4I Research published “Non-alcoholic steatohepataitis (NASH) Pipeline Analys …
“Non-alcoholic steatohepataitis (NASH) Pipeline Analysis” gives comprehensive insights on the various drugs being developed for the treatment of NASH. The report covers all the drugs that are in various phases of development (Discovery, Preclinical & Clinical). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, antibodies, stem cell therapies, recombinant proteins and RNA-based therapeutics, but excludes symptom relief drugs, generic combinations and supplemental drugs. The report…
Growing Prevalence of NASH to Increase Adoption of Therapeutics
"The Report OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has itemized the addition of a new market research report to its report repository. The research publication is titled, “Opportunity Analyzer: NASH - Opportunity Analysis and Forecasts to 2026.” The statistical surveying study is a watchful inspection of the general market…
OpportunityAnalyzer: NASH - Opportunity Analysis and Forecasts to 2026
First described in 1980, nonalcoholic steatohepatitis (NASH) (ICD-10-CM = K75.81) is a condition that develops as a subgroup of nonalcoholic fatty liver disease (NAFLD) when excessive fat buildup is accompanied by liver cell injury and inflammation. NAFLD is defined by excessive fat accumulation in the form of triglycerides (steatosis) in the liver. Progression of this condition to NASH dramatically increases the risk of cirrhosis, liver failure, and hepatocellular carcinoma, and…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
